This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-17 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Bart Anderson, PhD
Senior Director of R&D at Exicure


Bart Anderson is the Senior Director of R&D at Exicure Therapeutics, where he leads Exicure’s pre-clinical discovery and development efforts across all mechanisms of action (with current emphasis on RNase H-mediated RNA knockdown, immunostimulation, and splice-modulation) and therapeutic areas, including neurology, ophthalmology, dermatology, and immuno-oncology.

Bart joined Exicure Therapeutics in 2015, becoming Biology Group Leader and now the Senior Director of R&D. Since joining the company, Exicure’s preclinical Spherical Nucleic Acid (SNA) oligonucleotide compounds have moved into clinical trials using antisense-mediated mRNA reduction (TNFα and IL17RA) in dermatology as well as immunostimulation (TLR9-agonist) in immuno-oncology, and investigation has expanded to include splice-modulating oligonucleotides and neurological disorders.

Agenda Sessions

  • Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain